Analysts Set Exagen Inc. (NASDAQ:XGN) PT at $11.43

Shares of Exagen Inc. (NASDAQ:XGN) have earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $11.4286.

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. TD Cowen reduced their target price on Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, February 24th. B. Riley Financial restated a “buy” rating and set a $8.00 price target (down from $18.00) on shares of Exagen in a research report on Friday, January 30th. Finally, BTIG Research dropped their price target on Exagen from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th.

Insider Buying and Selling at Exagen

In related news, CEO John Aballi sold 15,698 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $3.62, for a total transaction of $56,826.76. Following the transaction, the chief executive officer directly owned 687,299 shares of the company’s stock, valued at approximately $2,488,022.38. This trade represents a 2.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Balyasny Asset Management L.P. bought a new stake in shares of Exagen in the 2nd quarter worth approximately $5,017,000. Invesco Ltd. bought a new position in shares of Exagen during the 3rd quarter valued at $7,420,000. Mink Brook Asset Management LLC grew its holdings in shares of Exagen by 784.3% during the 4th quarter. Mink Brook Asset Management LLC now owns 353,727 shares of the company’s stock valued at $2,151,000 after purchasing an additional 313,727 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in Exagen in the 4th quarter worth $1,520,000. Finally, Millennium Management LLC purchased a new position in Exagen in the 3rd quarter worth $2,716,000. 75.25% of the stock is currently owned by institutional investors.

Exagen Stock Performance

Shares of XGN opened at $3.38 on Thursday. Exagen has a 12-month low of $2.77 and a 12-month high of $12.23. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35. The company has a market cap of $76.59 million, a PE ratio of -3.67 and a beta of 1.88. The stock has a 50-day moving average price of $4.30 and a 200-day moving average price of $7.58.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.